Online inquiry

IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3245MR)

This product GTTS-WQ3245MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets FCGRT gene. The antibody can be applied in Myasthenia Gravis (MG) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3245MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13395MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PR-1594804
GTTS-WQ4547MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-936564
GTTS-WQ9605MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ11912MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MLN-1202
GTTS-WQ6908MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ENB-0040
GTTS-WQ6290MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CS-1001
GTTS-WQ823MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-085
GTTS-WQ2897MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG827
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW